The Latest Breaking News from LLY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).

Investors cheered a breakthrough drug pricing agreement between President Donald Trump and Pfizer Inc. (NYSE:PFE), sparking a sector-wide surge in health care stocks that delivered the biggest rally in five years.

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).